Sintx Technologies Inc. 2026年季度报告

FORM 10-Q Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes☐No☒ 4,319,279 shares of common stock, $0.01 par value, were outstanding at May 8, 2026. Cash and cash equivalents$1,889$4,140Account and other receivables, net of allowance for credit losses of $11.0 and $2.4 Stockholders’ equity: SINTX Technologies, Inc.Condensed Consolidated Statements of Operations - Unaudited SINTX Technologies, Inc.Condensed Consolidated Statements of Stockholders’ Equity - Unaudited 1. Organization and Summary of Significant Accounting Policies The condensed consolidated financial statements include the accounts of SINTX Technologies, Inc. (“SINTX”, or the “Company”) andits wholly-owned subsidiaries, SINTX Armor, Inc. (“SINTX Armor”), SINTX Agribiotech, Inc., Sinaptic Surgical, LLC, andTechnology Assessment and Transfer, Inc. (TA&T) through February 19, 2025 (see Note 2), which are collectively referred to as “we”orthe“Company.”SINTX Technologies is an advanced ceramics company formed in December 1996 that develops andcommercializes materials, components, and technologies for medical, industrial and agribiotech applications. SINTX develops siliconnitride (Si₃N₄)-based biomedical solutions for musculoskeletal and antipathogenic medical device applications. The Company alsomanufactures advanced silicon nitride components for leading industrial customers operating in high-performance and mission-criticalapplications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been SINTX Core Business Biomedical Applications: Since its inception, SINTX has focused on medical-grade silicon nitride. SINTX biomedical products havebeen shown to be biocompatible, bioactive, antipathogenic, and to exhibit strong bone affinity. Spinal implants made from SINTXsilicon nitride have been successfully implanted in humans since 2008 in the U.S., Europe, South America, and Asia. In October 2025,SINTX received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SiNAPTIC® Foot & Ankle Osteotomy WedgeSystem, enabling SINTX’s commercial entry into reconstructive foot and ankle surgery in the U.S. In March 2026, a SiNAPTIC Antipathogenic Applications: SINTX believes that by incorporating its unique composition of silicon nitride antipathogenic powderinto products such as face masks, drapes, filters, sutures, and wound care devices, it is possible to manufacture surfaces that inactivate Industrial Applications:SINTX manufactures advanced silicon nitride ceramic components for industrial customers operating indemanding technical and high-performance environments. The Company’s silicon nitride materials are utilized in applicationsrequiring exceptional mechanical strength, thermal stability, wear resistance, and corrosion resistance. Industrial applications havebecome an increasingly significant component of the Company’s commercial activities, with SINTX collaborating with industrial The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO9001:2015, ISO 13485:2016 certified, and AS9100D certified. The Company’s products are primarily sold in the United States. Basis of Presentation These unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of theUnited States Securities and Exchange Commission (“SEC”) and include all assets and liabilities of the Company. SEC rules and regulations allow the omission of certain information and footnote disclosures normally included in financial statementsprepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) so long as the statements are notmisleading. In the opinion of management, these financial statements and accompanying notes contain all adjustments (consisting ofnormal recurring adjustments) necessary to present fairly the financial position and results of operations for the periods presentedherein. These condensed consolidated financial statements should be read in conjunction with the consolidated audited financial Segment Informatio